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ABSTRACT
Integrins have been suggested as possible targets in anticancer therapy. Here we 
show that knockdown of integrins αVβ3, αVβ5, α3β1 and α4β1 and pharmacological 
inhibition using a cyclo-RGD integrin αVβ3/αVβ5 antagonist sensitized multiple high-
grade glioma cell lines to temozolomide (TMZ)-induced cytotoxicity. The greatest 
effect was observed in LN229 cells upon integrin β3 silencing, which led to inhibition 
of the FAK/Src/Akt/NFκB signaling pathway and increased formation of γH2AX foci. 
The integrin β3 knockdown led to the proteasomal degradation of Rad51, reduction of 
Rad51 foci and reduced repair of TMZ-induced DNA double-strand breaks by impairing 
homologous recombination efficiency. The down-regulation of β3 in Rad51 knockdown 
(LN229-Rad51kd) cells neither further sensitized them to TMZ nor increased the 
number of γH2AX foci, confirming causality between β3 silencing and Rad51 reduction. 
RIP1 was found cleaved and IκBα significantly less degraded in β3-silenced/TMZ-
exposed cells, indicating inactivation of NFκB signaling. The anti-apoptotic proteins 
Bcl-xL, survivin and XIAP were proteasomally degraded and caspase-3/-2 cleaved. 
Increased H2AX phosphorylation, caspase-3 cleavage, reduced Rad51 and RIP1 
expression, as well as sustained IκBα expression were also observed in mouse glioma 
xenografts treated with the cyclo-RGD inhibitor and TMZ, confirming the molecular 
mechanism in vivo. Our data indicates that β3 silencing in glioma cells represents a 
promising strategy to sensitize high-grade gliomas to TMZ therapy.
INTRODUCTION
Despite constant progress in medical care, high-
grade gliomas (WHO grade III – anaplastic astrocytomas 
and grade IV–glioblastomas) remain incurable. Ionizing 
radiation (IR) combined with the methylating anticancer 
drug temozolomide (TMZ) represents the standard 
therapy of these tumors [1]. TMZ induces various DNA 
adducts including O6-methylguanine (O6MeG), which 
is responsible for the anticancer activity. O6MeG can be 
repaired by the DNA repair protein O6-methylguanine-
DNA methyltransferase (MGMT). In the absence 
of MGMT, O6-MeG leads, via replication and the 
involvement of mismatch repair, to DNA double-strand 
breaks (DSBs). Importantly, ~40% of all malignant 
gliomas are negative for MGMT [2, 3] and TMZ therapy 
is particularly effective in these tumors [4, 5]. However, 
~60% of patients, whose tumors are proficient for MGMT, 
do not profit from the therapy. Thus, new strategies to 
overcome TMZ resistance in gliomas are urgently needed. 
One of these includes targeting of integrins. 
Integrins are heterodimeric transmembrane 
glycoprotein α/β receptors that mediate cell adhesion 
and directly bind components of the extracellular matrix 
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(ECM), thereby providing anchorage for cell motility 
and invasion. In addition, binding of integrins with 
ECM ligands induces a variety of intracellular signals 
and regulates cellular responses including proliferation, 
survival, migration and differentiation [6]. Activation of 
integrin receptors results in the association of multiple 
protein complexes, allowing integrins to transmit 
biochemical signals via tyrosine kinases such as focal 
adhesion kinase (FAK) or Src [7]. Integrin-associated 
proteins are involved in all major signal transduction 
pathways critical in determining the cell response to 
cytotoxic agents. 
Integrins αVβ3 and αVβ5 are broadly expressed not 
only on blood vessels in brain tumors (glioblastomas), 
but also in tumor cells [8, 9]. Various pharmacological 
approaches for modulation of integrin signaling have 
been explored including antibodies and peptide-based 
agents [6, 10]. Indeed, treatment of tumors by integrin 
antagonist cilengitide (CGT) in the orthotopic brain 
model in vivo reduced tumor growth [11]. A clinical 
phase II study revealed that the concomitant and adjuvant 
addition of CGT, a cyclic αVβ3/αVβ5 RGD mimetic 
[12], to the standard TMZ radio-chemotherapy showed 
promising activity in glioblastoma patients with MGMT 
promoter methylation [13]. Unfortunately, in the phase 
III study (CENTRIC) CGT failed to show advantage in 
comparison to the standard treatment [14]. One reason 
out of many for this failure could be that mainly αVβ3 
and αVβ5 expressed on endothelial cells were targeted, 
while integrins expressed on tumor cells were inefficiently 
blocked [15, 16]. Despite this inconclusive trial, integrins 
still remain an attractive target for cancer therapy, which is 
strongly supported by the present study. Also, the newest 
data conducted on tumor material of the CORE study 
(failed to show benefit of CGT in patients with MGMT 
positive tumors) [17] showed that αVβ3 expression 
correlates with better OS and PFS in CGT-treated patients 
with tumors expressing MGMT [18].
Since integrins promote many essential cellular 
functions, their knockdown by means of siRNA might be 
a promising approach to enhance the efficacy of tumor 
therapy. Here, we particularly focused on molecular 
pathways/signaling initially caused by silencing of 
integrin β3 in glioblastoma cells. We show in cell culture 
in vitro and in a xenograft model in vivo that β3 silencing 
suppresses DNA repair of TMZ-induced DSBs impairing 
homologous recombination (HR). Furthermore we provide 
evidence of the involvement of the Akt/NFκB signaling 
pathway in this process.
RESULTS 
Determination of integrin status in human 
malignant glioma cell lines
Expression of integrin heterodimers (α3β1, 
α4β1, αVβ3 and αVβ5), together with MGMT and p53 
status in a panel of ten cell lines is shown in Table 1 
and Supplementary Figure S1 (histograms). The p53 
and MGMT activity (Table 1) were determined before 
[2, 3, 19]. Only two of the glioma cell lines (GBP61 
and U138MG) were shown to express all four integrin 
heterodimers. Nine out of ten cell lines express αVβ3, 
indicating that this integrin might be a suitable therapeutic 
target for malignant gliomas. A total of seven cell lines 
were shown to express the α4β1 integrin. Out of the 
nine cell lines expressing αVβ3, we selected four lines 
for further investigation. These cell lines do not show 
MGMT activity which enabled us to achieve maximum 
TMZ cytotoxicity without MGMT inhibitor. We chose 
the U138MG cell line, showing expression of all four 
integrins, the glioblastoma cell lines LN229 and LN308, 
expressing αVβ3 and α4β1, but are characterized by 
a different p53 status [19, 20] and the U87MG cell line 
expressing αVβ3 and αVβ5, also used in the xenograft 
model. 
Integrin β3, β5, αV, α3 and α4 silencing sensitizes 
malignant glioma cells to TMZ
In all analyzed high-grade glioma cell lines (LN229, 
LN308, U138MG, U87MG) the integrin subunit-specific 
siRNA transfection led to reduction in expression of 
corresponding integrins, whereas the control-siRNA had 
no effect. A representative example of integrin expression 
and of effective silencing, as quantified by mean 
fluorescence intensity (MFI), is shown for the LN229 cell 
line (Figure 1A). In order to concomitantly reduce the 
expression of αVβ3 and αVβ5, in some experiments cells 
were transfected with integrin αV-specific siRNA.
Silencing of the corresponding integrin subunits in 
the cell lines LN229, LN308, U87MG and U138MG clearly 
increased sensitivity to TMZ compared to the control-
siRNA, as shown by the MTT assay (for LN229 cell line, 
see Figure 1B–1D, for other cell lines, see Supplementary 
Figure S2–S4). Of note, the cells were exposed to TMZ 
for six days. Growth rates of the cell lines upon siRNA 
transfection were slowed down by 20% at maximum 
relative to the non-transfected control. We also determined 
reproductive cell survival by colony formation assay (LN229 
Figure 1E and U138MG Supplementary Figure S2B) 
showing that each of the integrin-specific siRNAs led to a 
reduced clonogenic survival as compared to control-siRNA. 
The silencing of the integrin subunits β3 led to the strongest 
sensitization effect upon TMZ exposure in all analyzed cell 
lines indicating that the integrin αVβ3 plays a crucial role in 
mediating TMZ sensitivity. The strongest sensitization effect 
was achieved in LN229 cells, thus we used this cell line for 
all further experiments. 
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Figure 1: Integrin expression and sensitization to TMZ after specific integrin silencing. (A) LN229 cells were transfected 
with integrin αV-, α4-, β3-, β5-or control non-silencing (ns)-siRNA, 48 h later the cells were detached by EDTA and the expression of αVβ3, 
αVβ5, αV, and α4β1 was measured by flow cytometry. As a negative control, mouse IgG antibodies were used. The expression i.e. effective 
integrin silencing was quantified by mean fluorescence intensity (MFI) and represented as relative to expression in cells transfected with 
control non-silencing (ns)-siRNA that was set to 1. The data presented are representative of three independent experiments with similar 
results. (B–D) LN229 cells were transfected with integrin αV-, α4-, β3-, or ns-siRNA, and 24 h later collected by trypsinization and seeded 
for cell viability assay (MTT). After another 24 h the cells were treated with TMZ and after six days metabolic activity was assessed. The 
data are the mean of three independent experiments in quadruplicates ± SD. (E) LN229 cells were seeded in 6-well cluster and 24 h later 
transfected with integrin αV-, α4-, β3- or ns-siRNA. After additional 24 h cells were re-seeded for colony formation assay at the density of 
1000 cells per 6-well dish, and 24 h later exposed to TMZ or left unexposed. Fourteen days later the visible colonies were fixed, stained 
and counted. The plating efficiency of the cell lines after integrin silencing was ~60–70%. Unexposed integrin-specific and ns-control were 
set to 100%. The data are the mean of three independent experiments ± SD. *p ≤ 0.05 significant, **p ≤ 0.01 very significant, ***p ≤ 0.005 
highly significant, ****p ≤ 0.001 most significant. 
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Integrin silencing and cyclo-RGD integrin 
inhibitor sensitize glioma cells to TMZ-induced 
apoptosis
TMZ predominantly induces apoptosis in 
malignant glioma cells as a very late event [21]. A 
concentration of 100 µM TMZ was shown to be an 
optimal concentration in glioma cell culture experiments 
[21, 22] and is also achievable in the blood plasma. 
Integrin silencing sensitized cells to TMZ, as shown by 
the subG1 fraction, determined at 96, 120 and 144 h (for 
LN229 and U87MG, see Figure 2A–2D; for LN308 and 
U138MG, see Supplementary Figure S5A and S6A). The 
same was true using the annexin V assay, pointing to a 
specific induction of apoptosis, whereas the frequency of 
necrosis remained constant (for LN229 and U87MG, see 
Figure 3A, left panel). In support of this, increased activity 
of the executive caspase-3/7 was observed (for LN229 
and U87MG, see Figure 3A, right panel; for LN308 and 
U138MG, see Supplementary Figure S7A, S7B, left 
panel). Of note, integrin silencing slowed down the cells 
in general but did not cause any significant changes in the 
cell cycle phase distribution (data not shown).
In order to elucidate whether the sensitization effect 
towards TMZ can also be achieved by administration of a 
cyclo-RGD inhibitor, we used an integrin antagonist that 
is similar to CGT. This inhibitor predominantly inhibits 
integrin αVβ3 and, albeit to a lower extent, αVβ5, 
thus the imposed effects can be primarily attributed to 
inhibition of αVβ3. As shown by the increased subG1 
fractions all glioma cell lines were sensitized to TMZ, 
independent of their p53 status (Figure 2E, Figure  2F, 
Supplementary Figure S5B and Supplementary 
Figure S6B). The strongest inhibitor-mediated 
sensitization effect, in analogy to integrin β3 and αV 
knockdown, was achieved in LN229 cells (Figure 2E). 
The induction of apoptosis upon combination treatment 
with the cyclo-RGD inhibitor and TMZ was confirmed 
by the annexin V assay (Figure 3B, upper panel) and 
induction of the caspase-3/7 activity (Figure 3B, lower 
panel, Supplementary Figure S7A, S7B, right panel).
Effect of αVβ3 silencing on the number of 
γH2AX foci upon TMZ exposure
To investigate whether integrin signaling is 
associated with the DNA damage response and DNA 
repair, we determined the induction of γH2AX foci in 
integrin-silenced cells exposed to TMZ. We observed 
that the number of TMZ-induced γH2AX foci was 
enhanced by all integrin-specific siRNAs in LN229 cells 
(Figure  4A–4D) and U138MG cells (Supplementary 
Figure S8), indicating inefficient repair of DSBs. In 
unexposed controls, none of the siRNAs was able to 
induce γH2AX foci on its own. The repair foci were 
verified by co-localization of γH2AX and 53BP1 (data 
not shown). Since the sensitization to TMZ using either 
β3- or αV-siRNA in LN229 cells was comparable (see 
Figure 1B, 1C and 1E), the increased number of γH2AX 
foci is likely caused by silencing of αVβ3 but the effect of 
αVβ1 cannot be excluded. 
Table 1: Integrin expression in malignant glioma cell lines
Cell line p53 status (rest activity) MGMT activity (fmol/mg protein) α3β1 α4β1 αvβ3 αvβ5
T98MG mt (0%) + (428) − + + +
GBP61 wt + (293) + + + +
LN18 mt (1%) + (205) − + + +
LN229 wt − (4) − + + −
LN308 mt (deletion) − (1) − + + (+)
LN319 mt (1%) − (0) + (+) (+) +
LN428 mt (0%) − (0) − − + (+)
D247MG wt − (19) − + − −
U87MG wt − (1) − − + +
U138MG mt (9%) − (2) + + + +
wt, wild-type; mt, mutant; “+“, relative  strong expression  (MFI = 0.4–1.0); “(+)“, relative weak expression (MFI = 0.1–0.4); 
“–“, no expression (MFI = 0). Mean fluorescence intensity (MFI) was set to 1 relative to the positive control (αVβ3 signal in 
GBP61 cells). 
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Effect of αVβ3 silencing on the number of Rad51 
foci and HR efficiency upon TMZ exposure
Since increased frequency of γH2AX foci pointed 
to a reduced DSB repair, we examined whether and to 
what extent the number of Rad51 foci is modulated by 
silencing of αV or β3 upon TMZ exposure. The data 
shows that the number of Rad51 foci constantly declined 
during the exposure time (48–96 h, Figure 5A) whereas 
the γH2AX foci remained at high level, indicating that 
HR was compromised. The number of Rad51 foci in 
LN229 cells after αV or β3 knockdown was dramatically 
reduced 96 h after TMZ exposure as compared to the 
number of foci at 48 h. In contrast, the number of Rad51 
foci in cells transfected with control-siRNA increased 
with time and was higher at 72 and 96 h in comparison 
to 48 h upon exposure to TMZ (see Figure 5A). Whereas 
Figure 2: Modulation of apoptosis induction by integrin silencing or pharmacological inhibition. (A, B) LN229 and (C, D) 
U87MG cells were transfected with integrin β3-, α4-, β5- or ns-siRNA, and 48 h later exposed to 100 µM TMZ. After 96, 120 and 144 h the 
cells were subjected to subG1 flow cytometric analysis. The data are the mean of two independent experiments in duplicates ± SD. (E, F) 
LN229 and U87MG cells were pre-treated with a cyclo-RGD integrin antagonist (10 µg/mL) alone, or exposed, in addition, to 100 µM 
TMZ. 120 h later, the cells were subjected to subG1 flow cytometric analysis. The data are the mean of two independent experiments in 
duplicates ± SD. *p ≤ 0.05 significant, **p ≤ 0.01 very significant, ***p ≤ 0.005 highly significant, ****p ≤ 0.001 most significant. n.s., 
not significant.
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Figure 3: Induction of apoptosis/necrosis and caspase-3/7 activity. (A) (left panel): LN229 and U87MG cells were transfected 
with integrin β3-, α4-, β5- or ns-siRNA, respectively, and 48 h later exposed to TMZ (100 µM). After 96, 120 and 144 h the cells were 
subjected to subG1 flow cytometric analysis. The data are the mean of two independent experiments in duplicates ± SD. (A) (right panel): 
LN229 and U87MG cells were transfected with integrin β3-, α4-, β5- or ns-siRNA, respectively, and 24 h later re-seeded in the 96-well 
plate. After additional 24 h cells were treated with TMZ (100 µM) and 120 h later the caspase-3/7 activity was determined. (B) LN229 and 
U87MG cells were pre-treated with a cyclo-RGD integrin antagonist (10 µg/mL) alone, or exposed, in addition, to TMZ (100 µM). 120 h 
later, the cells were subjected to annexin V/PI staining and to caspase-3/7 analysis. The data are the mean of two independent experiments 
in duplicates ± SD. *p ≤ 0.05 significant, **p ≤ 0.01 very significant, ***p ≤ 0.005 highly significant, ****p ≤ 0.001 most significant. n.s., 
not significant.
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all Rad51 foci co-localized with γH2AX foci in control-
siRNA transfected cells (indicating ongoing HR) upon 
integrin αV and β3 knockdown, a lot of γH2AX foci did 
not co-localize with Rad51, indicating persistent DSBs 
(Figure 5B). The results were supported by a significant 
reduction of HR efficiency in LN229 cells transfected with 
β3-siRNA and treated with TMZ (Figure 4B, for qPCR 
melting curves, see Supplementary Figure S9).
Reduction in the number of Rad51 foci is a 
consequence of αVβ3 integrin silencing
In order to examine whether the reduced number 
of Rad51 foci is a consequence of integrin β3 silencing, 
we utilized a cell clone with stable Rad51 knockdown 
(LN229-Rad51kd), which was shown to be hypersensitive 
to TMZ [23]. In this clone, the integrin subunit β3 or αV 
was silenced and cells were treated with a low TMZ 
concentration (2.5–20 µM). As shown in Figure 6A–6B, 
neither silencing of β3 nor αV had impact on TMZ-induced 
cytotoxicity in the LN229-Rad51kd clone. There was 
also no difference in the induction of γH2AX foci in the 
LN229-Rad51kd clone upon β3 knockdown (Figure 6C). 
Conversely, the parental LN229 cells transfected with 
control-siRNA and exposed to 10 µM TMZ were able to 
significantly repair DSBs, whereas the cells transfected 
with integrin β3-siRNA were unable to do so, even at this 
low TMZ concentration (Figure 6D). Collectively, the data 
indicate that the increased TMZ cytotoxicity upon αVβ3 
knockdown is due to a reduced Rad51-dependent repair 
of DSBs.
Figure 4: Induction of γH2AX foci upon TMZ/integrin silencing. (A, C, D) LN229 cells were transfected with β3-, αV-, α4- or 
ns-siRNA and exposed to 100 µM TMZ. At indicated time points, the cells were stained for γH2AX. Counterstaining of the nuclei was 
performed using TO-PRO-3. The data are the mean of two independent experiments in duplicates ± SD. (B) Efficiency of homologous 
recombination (HR) after transfection of LN229 cells with control-siRNA or β3-siRNA alone or combined with 100 µM TMZ. Cellular 
DNA was extracted 96 h after TMZ exposure. Samples were standardized with universal primers, detecting the plasmid backbone for 
control of transfection efficiency. HR activity in control-siRNA transfected cells was set to 100%. The data are the mean of two independent 
experiments in duplicates ± SD. *p ≤ 0.05 significant, **p ≤ 0.01 very significant, ***p ≤ 0.005 highly significant, ****p ≤ 0.001 most 
significant. n.s., not significant.
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Modulation of integrin signaling kinases and 
Rad51 expression by β3 silencing and TMZ
We also analyzed whether the signaling kinases 
FAK, Src and ILK are modulated upon β3 knockdown. 
It is well known that tyrosine 397 of the FAK protein 
is the main target of autophosphorylation, which leads 
to the activation of FAK, and renders pFAK (Y397) as 
high-affinity partner for binding of Src [24]. Similarly, 
the autophosphorylation at Y418 is required for full 
catalytic activity of Src [25]. Another catalytic adaptor 
that directly binds the β1 and β3 integrin cytoplasmic 
tails is ILK [26]. The data show that pFAK and pSrc 
expression was reduced 24–96 h upon TMZ treatment 
(following 48 h β3-siRNA transfection) (Figure 7A), 
while the expression of ILK was not changed (data not 
shown), indicating that integrin αVβ3 signals in glioma 
cells through pFAK and pSrc. In line with this, β3 
silencing also resulted in dephosphorylation of the pro-
survival kinase Akt (Figure 7A). Most interestingly, TMZ 
exposure led to a reduction in Rad51 protein expression, 
but upon β3 silencing the reduction was strongly 
Figure 5: Induction of Rad51 foci upon TMZ/αVβ3 integrin silencing. (A) LN229 cells were transfected with αV-, β3- or 
ns-siRNA and exposed to 100 µM TMZ. At indicated time points, the cells were stained for Rad51 and γH2AX. Counterstaining of the 
nuclei was performed using TO-PRO-3. The data are the mean of two independent experiments in duplicates ± SD. *p ≤ 0.05 significant, 
**p ≤ 0.01 very significant, ***p ≤ 0.005 highly significant, ****p ≤ 0.001 most significant. n.s., not significant. (B) The representative 
nuclei at 72 h upon TMZ exposure showing co-localization (overlay) of Rad51 foci (green staining) and γH2AX foci (red staining). The 
nuclei were stained with TO-PRO-3 (blue staining). 
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enhanced and started even earlier i.e. 24 h after TMZ 
exposure. Reduction of Rad51 was due to proteasomal 
degradation (Figure 7B) and was most pronounced 120-
144 h upon TMZ exposure and paralleled the H2AX 
phosphorylation (Figure 7C). Since Rad51 degradation 
was also observed in control-siRNA transfected cells, 
albeit to a much lower extent, this effect appears to 
result partially from TMZ itself, but is strongly amplified 
following β3 silencing (Figure 7A, 7C).
Modulation of apoptosis pathways by β3 
silencing combined with TMZ
It has been shown that dephosphorylation of Akt 
might be an important trigger of apoptosis through direct 
phosphorylation of X-linked inhibitor of apoptosis (XIAP) 
[27]. Indeed, following Akt dephosphorylation (Figure 7A) 
XIAP was proteasomally degraded (Figure 8A), which led 
to a subsequent degradation of survivin and Bcl-xL (Figure 
8A). Reduced expression of these anti-apoptotic proteins led 
to cleavage of caspase-3 and reduction of its downstream 
target pro-caspase-2 (Figure 8A, left panel). Interestingly, 
the late activation of caspase-2 (120–144 h) coincided with 
reduction in RIP1 protein (Figure 8B, left panel), which is 
one of its putative targets [28]. In line with this, RIP1 kinase, 
although reduced in its protein level, was not proteasomally 
degraded (Figure 7B, right panel). RIP1 itself is a crucial 
factor for activation of NFκB in DNA damage-induced 
apoptosis [29]. Moreover, IκBα, the inhibitor of NFκB, 
was found less degraded in β3-siRNA than in control-
siRNA transfected cells upon TMZ treatment (Figure 7B), 
suggesting incomplete activation of NFκB. 
Reduction in NFκB activity by pharmacological 
inhibition or by integrin silencing reinforces 
reduction in Rad51 upon TMZ treatment
Recently it was shown that NFκB can directly 
support HR by binding to the BRCA1-CtiP complex, 
leading to a more efficient Rad51-dependent repair of 
DSBs [30]. Therefore, we analyzed whether incomplete 
activation of NFκB may influence Rad51 expression upon 
TMZ exposure. To this end, LN229 cells were exposed 
to TMZ and 24 h later treated with a specific inhibitor of 
Figure 6: Determination of cell viability and induction of γH2AX foci in Rad51 knockdown cells upon TMZ/
αVβ3 integrin silencing. (A, B) LN229-Rad51kd cells were transfected with αV-, β3-, or ns-siRNA and 48 h later exposed to TMZ 
(2.5–20 µM) for determination of cell viability in the metabolic MTT assay. (C) Time-dependent induction of yH2AX in LN229-
Rad51kd cells transfected with β3-or ns-siRNA, non-exposed or exposed to 10 µM TMZ. (D) Time-dependent induction of γH2AX foci 
in LN229 cells transfected with β3- or ns-siRNA, non-exposed or exposed to 10 µM TMZ. The data are the mean of two independent 
experiments in duplicates ± SD. *p ≤ 0.05 significant, **p ≤ 0.01 very significant, ***p ≤ 0.005 highly significant, ****p ≤ 0.001 most 
significant. n.s., not significant.
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NFκB. As shown in Figure 8C, 96 h upon TMZ exposure 
Rad51 protein expression was reduced, but the effect 
was significantly more pronounced following NFκB 
inhibition. In line with this, the reporter assay showed a 
strongly reduced NFκB activity upon TMZ/β3 silencing 
(see Figure 8D). TMZ itself and TMZ/control-siRNA 
elevated NFκB activity, as reported [31]. Altogether, 
the data indicates the incomplete activation of NFκB 
observed upon TMZ/β3 silencing could at late time points 
additionally decrease Rad51 expression and thus suppress 
HR activity. 
Verification of in vitro data in xenograft model 
in vivo
To verify the molecular mechanism in vivo and 
to demonstrate that inhibition of integrin signaling has 
impact on DNA repair and the cytotoxic response of 
glioma cells to TMZ, we treated nude mice bearing 
U87MG tumor xenografts with the cyclo-RGD inhibitor 
and challenged them with TMZ. As shown in Figure 9A, 
expression of γH2AX and cleaved caspase-3, as well as 
reduction in Rad51 and RIP1 expression and sustained 
level of IκBα expression were significantly more enhanced 
in tumor extracts from animals treated with the inhibitor 
and TMZ, in comparison to non-treated mice and mice 
treated with the RGD inhibitor or TMZ only, revealing the 
same molecular mechanism to occur also in vivo. Similar 
to in vitro results, inhibition of αVβ3 by the RGD inhibitor 
enhanced the TMZ response and furthermore triggered 
tumor regression (examples are shown in Figure 9B). 
Effect of integrin αV silencing on migration of 
glioma cells
In order to substantiate the decisive role of 
integrins αV as feasible targets not only for sensitization 
to alkylation-based glioma therapy in terms of induction 
of apoptosis but also to combat metastasis, we conducted 
migration assays. We observed that upon knockdown of 
different integrins in LN229 (Figure 10A) and U138MG 
(Figure 10B) cells migration was significantly decreased, 
but the most dramatic effect was observed in LN229 
cells upon αV knockdown. A similar highly potent effect 
of integrin αV knockdown was observed in U138MG 
cells, reflecting the involvement of both αVβ3 and 
αVβ5 in migration. In U138MG cells the β3 knockdown 
inhibited migration significantly more efficient than 
knockdown of β5, suggesting again that integrin αVβ3 is 
a potential therapeutic target for inhibition of metastasis. 
The knockdown of α4 in U138MG cells significantly 
inhibited migration but in LN229 cells did not affect 
migration at all. 
DISCUSSION
Some integrin-targeting strategies like monoclonal 
antibodies and small molecules as CGT, which was 
shown to inhibit the activation of integrins αVβ3 and 
αVβ5 in the orthotopic brain model thereby inhibiting 
angiogenesis [11] have been tested in clinical trials [6]. 
It has been shown that αV antagonists inhibit cancer 
growth independent of the anti-angiogenic effect [32]. 
Co-delivery of siRNAs with anticancer agents provides 
Figure 7: Expression of integrin signaling kinases, DNA repair proteins and apoptotic factors upon TMZ/αVβ3 integrin 
silencing. (A, B) LN229 cells were transfected with control-siRNA (si(ns)) or β3-siRNA (si(β3)) and 48 h upon transfection exposed to 
100 µM TMZ. A. At different time points (24-96 h) upon TMZ exposure, whole-cell extracts were isolated and subjected to western blot 
analysis of pSrcY418, Src, pFAKY397, FAK, pAktS473, Akt and Rad51. B. The proteasomal inhibitor MG132 (10 µM) was not added or added 
to the cells 24 h after addition of TMZ, and protein extracts examined for expression of Rad51 (con: TMZ-unexposed cells). Hsp90 was 
used as loading control. (C) LN229 cells were transfected with si(ns) or si(β3) and 48 h later exposed to 100 µM TMZ. The cells were 
collected at 96-144 h upon TMZ exposure and subjected to western blot analysis of unphosphorylated and phosphorylated H2AX (γH2AX) 
and Rad51. β-actin was used as loading control.
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promising option for an improved chemotherapeutic 
effect. Various nanocarriers, which are not devoid of 
limitations, have been developed to deliver siRNA and 
drugs. The major challenge for siRNA-based therapeutics 
includes minimizing the potential off-target effects and 
controlling the specificity of the siRNA. However, it is 
anticipated that the research on combination delivery of 
siRNA and chemotherapeutics will progress with increase 
in the knowledge and innovative delivery strategies [33].
Although in a phase I/II study CGT had a beneficial 
effect for patients having tumors with MGMT promoter 
methylation [13], this positive curative effect was not 
confirmed in the phase III (CENTRIC) study [14]. In our 
opinion, the failure of the study could be explained by 
the CGT pharmacokinetics. In the CENTRIC study, CGT 
was applied as anti-angiogenic drug and probably poorly 
reached the tumor. In this context, it is important to note 
that the effectiveness of anti-integrin drugs was critically 
assessed before [34]. Thus, it was shown that a too low 
antagonist concentration instead of inhibiting, promotes 
Figure 8: Expression of different pro- and anti-apoptotic factors upon TMZ/αVβ3 integrin silencing. (A) LN229 cells 
were transfected with integrin β3- or ns-siRNA and 48 h upon transfection exposed to 100 µM TMZ (left panel) or additionally exposed to 
MG132 (10 µM) 24 h after begin of TMZ treatment (right panel). The cells were collected 96-144 h after TMZ exposure and subjected to 
western blot analysis of XIAP, survivin, Bcl-xL and caspase-3/caspase-2 expression. β-actin and Hsp90 were used as loading control. (B) 
LN229 cells were transfected with integrin β3- or ns-siRNA and 48 h later exposed to 100 µM TMZ (left panel) or additionally exposed 
to MG132 (10 µM) 24 h after begin of TMZ treatment (right panel). The cells were collected at different times upon TMZ exposure and 
subjected to western blot analysis of RIP1 and IκBα. (C) Time-dependent expression of Rad51 after treatment of LN229 cells with NFκB 
inhibitor (10 µM NFκBi), 100 µM TMZ, or a combination of both (TMZi). (D) NFκB activity was determined by the dual luciferase reporter 
assay. Cell lysates were analyzed in triplicates and standardized for transfection using a renilla luciferase construct. The unexposed controls 
(con, si(ns), si(β3)) were set to 1. NFkBi: NFκB inhibitor (10 µM). The data are the mean of two independent experiments in duplicates ± 
SD. *p ≤ 0.05 significant, **p ≤ 0.01 very significant, ***p ≤ 0.005 highly significant, ****p ≤ 0.001 most significant.
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angiogenesis [35]. Another reason for the failure might be 
the opposite action of radiotherapy and CGT. It was shown 
that IR induces expression of αVβ3 in human endothelial 
[32] and glioma cells [36]. If this is the case, concurrent 
integrin antagonists may be beneficial only in a TMZ 
mono-therapy setting. In spite of the negative outcome 
of the CENTRIC and CORE study, the data suggests that 
integrins remain an attractive target for cancer therapy.
Based on the data obtained in a panel of ten 
glioblastoma cell lines and the fact that αVβ3 represents 
the most frequently expressed integrin heterodimer on 
malignant gliomas [37], we focused on its impact on 
TMZ-induced cytotoxicity and repair in vitro and in vivo. 
Moreover, the expression of αVβ3 in tumor cells and 
vessels, but not of other αV integrins, was shown to be 
dependent on tumor grade, and αVβ3 expression in tumor 
cells may have a prognostic impact [38]. We could show 
that silencing of all of the respective integrin subunits (αV, 
α3, α4, β3 and β5) sensitized glioblastoma cell lines to 
TMZ but the silencing of αVβ3 was the most powerful. 
Moreover, cytotoxicity of TMZ was also enhanced in 
glioblastoma cell lines using a cyclo-RGD antagonist, 
which inhibits integrin αVβ3 comparably to CGT but 
needs much higher concentrations to antagonize αVβ5. 
Since the applied concentrations were rather low, we 
suppose that the sensitizing effect of the inhibitor is 
primarily attributed to silencing of αVβ3. The decisive 
role of integrins αV for glioma therapy response 
was corroborated by decreased migration after their 
knockdown in LN229 and U138MG cells, thus indicating 
decreased metastatic potential. In LN229 cells the effect of 
integrin αV knockdown was the most dominant, indicating 
that not only integrin αVβ3, but very likely also integrin 
αVβ1 is involved in cell migration. A similar highly 
potent effect of integrin αV knockdown was observed 
in U138MG cells, reflecting the involvement of several 
αV integrin heterodimers in migration, i.e. at least αVβ3 
and αVβ5. In U138MG cells the β3 knockdown inhibited 
migration significantly more efficient than knockdown 
of β5, suggesting again that integrin αVβ3 is not only a 
potential therapeutic target for sensitization to TMZ but 
also for inhibition of metastasis. 
Our results show that silencing of the integrins 
α3β1, α4β1, αVβ3 and αVβ5 strongly enhanced the 
TMZ-induced formation of DSBs, as determined by 
γH2AX foci induction. This was accompanied by a 
significantly reduced expression of the Rad51 protein 
due to proteasomal degradation, leading to a decline in 
the Rad51 foci level. Rad51 represents a rate-limiting 
factor for repair of TMZ-induced DSBs by HR [23]. 
Indeed, LN229 cells showed a decreased HR efficiency, 
indicating that decreased expression of Rad51 abrogates 
the repair of DSBs. This conclusion is further supported 
by the finding that β3 silencing was neither able to further 
sensitize Rad51 knockdown cells to low-dose TMZ nor 
to enhance the number of TMZ-induced γH2AX foci. 
Thus suppression of DSB repair upon β3 silencing equals 
the effect of a direct Rad51 inhibition which is in line 
with literature data [39]. As expected, inhibition of αVβ3 
by the cyclo-RGD antagonist in combination with TMZ 
in the glioma xenograft model, led to pronounced tumor 
regression and showed consistently reinforced γH2AX 
phosphorylation and caspase-3 cleavage, strongly 
reduced Rad51 and RIP1 expression, and revealed a 
persistent IκBα expression in tumors in situ compared to 
mice treated with TMZ alone. Thus, the data obtained in 
cell culture and in vivo reveals a very similar molecular 
mechanism, showing that inhibition of αVβ3 affects 
the DNA repair capacity and ameliorates the cytotoxic 
response of glioma cells to TMZ.
The proteasomal degradation of Rad51 seems to 
be an important mechanism in sensitizing cancer cells 
by suppressing HR [40, 41]. In our hands, the efficiency 
of non-homologous end-joining upon TMZ/β3 silencing 
was not affected, as shown by the radioactive DNA-PKcs 
activity assay (Supplementary Figure S10), contrary 
Figure 9: Expression of DNA repair and apoptotic factors in mice xenografts. (A) Nude mice (Balb/c nu/nu, two animals per 
each group) with U87MG xenografts were left untreated (con) or intraperitoneally injected with cyclo-RGD integrin antagonist (RGD), 
TMZ, or a combination of both (RGD+TMZ). After regression time of three weeks, tumors were removed, proteins extracted and subjected 
to western blot analysis of γH2AX, Rad51, RIP1, IκBα and cleaved caspase-3. β-actin was used as loading control. (B) Representative 
images of the nude mice, showing regression of tumors in TMZ- and RGD/TMZ-treated animals. 
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to the published data for IR/β1 silencing [42]. Upon 
TMZ/β3 silencing we observed a modest slow-down 
in progression of cells in all phases of the cell cycle, as 
already mentioned. Nevertheless, we cannot exclude that 
this moderate arrest in S- and G2-phase contributes to the 
decreased Rad51 levels and impairment of HR. 
Integrin-mediated adhesion modulates the 
expression of proteins like PI3K/Akt, Bad, Bcl-2, Bcl- xL, 
survivin, XIAP, p27Kip, and activation of MAP kinase 
pathways, activation of PARP and NFκB [43]. Thus, we 
further analyzed which signaling pathways and apoptotic 
factors are altered upon integrin silencing. Our data 
revealed that integrin αVβ3 transmits signals through 
pFAK, pSrc and pAkt, which is in line with results 
showing that Src silencing enhanced the cytotoxic effect 
of TMZ in LN229 cells [44]. The same inhibition of 
FAK/Src/Akt in glioma cells was also shown upon CGT 
[45]. In our experiments β3 silencing led to reduction 
in phosphorylation and expression of XIAP, which is 
presumably associated with the observed inactivation 
(dephosphorylation) of Akt [27]. The reduced expression 
of XIAP was also a result of proteasomal degradation 
and was associated with reduced expression of survivin, 
an essential mitotic and anti-apoptotic protein, which 
can be marked for degradation by the E3 ubiqutin ligase 
activity of XIAP [46]. Furthermore, we observed a 
reduced expression of the anti-apoptotic Bcl-xL protein, 
which might be explained through abrogation of Bad 
phosphorylation by Akt. In this case hypophosphorylated 
Bad could deliberate Bcl-xL from the complex allowing 
Bcl-xL degradation [27]. TMZ/β3 silencing finally led to 
activation of caspase-3 and a late decline in the level of 
pro-caspase-2, a known downstream target of caspase-3 
[47]. The activation of caspase-2 coincided with reduction 
Figure 10: Integrin subunit knockdown decreases migration. Cell migration was determined in (A) LN229 cells upon transfection 
with control-, α4-, αv- or β3-siRNA and (B) U138MG cells upon transfection with control-, α3-, α4-, αv-, β5- or β3-siRNA. 48 h after 
transfection, the cells were starved for 24 h and cell migration was measured in Boyden chambers. After 22 h, cells on the underside of 
the membrane were stained with crystal violet, photographed and counted. Averages of five microscope fields ± SD are shown. *p ≤ 0.05 
significant, **p ≤ 0.01 very significant, ***p ≤ 0.005 highly significant, ****p ≤ 0.001 most significant.
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in RIP1, which is a crucial factor for activation of NFκB in 
DNA damage-induced apoptosis [29, 48]. Since reduction 
in RIP1 expression could not be inhibited by the MG132 
proteasomal inhibitor, it might be a result of a direct 
cleavage by caspase-2, for which RIP1 was postulated 
to be a putative target [28]. Involvement of caspase-8 in 
RIP1 cleavage could be excluded since caspase-8 was 
not activated in our model (data not shown). In addition 
to reduced RIP1 expression at late time points, IκBα 
was stabilized upon TMZ/β3 silencing. Both, down-
regulation of RIP1 and enhanced stability of IκBα may 
lead to incomplete activation of NFκB at late time points, 
as supported by reduced NFκB activity in the reporter 
assay. NFκB can act as a pro-survival transcription factor 
[49–51]. Upon TMZ/β3 silencing, however, NFκB is 
unlikely to be involved in the transcriptional regulation 
of Bcl-xL, survivin and XIAP, since these factors were 
degraded by the proteasome. Besides being a transcription 
factor, NFκB can play a direct role in HR repair, 
stimulating Rad51 activity. In this case, NFκB regulates 
repair of DSBs in conjunction with BRCA1-CtiP complex 
[30] which might also be the case upon TMZ/β3 silencing. 
This assumption was further supported by the observation 
that pharmacological NFκB inhibition combined with 
TMZ accelerated the Rad51 degradation, in comparison 
to TMZ alone (see Figure 7C). Thereby NFκB inhibition 
recapitulates the effect of β3 silencing on the Rad51 
expression. However since Rad51 degradation was 
observed prior to the impairment of the NFκB function 
following β3 silencing, reduced NFκB activity cannot 
be the initial trigger. It is conceivable, however, that it 
suppresses Rad51 expression and HR activity at late time 
points, thereby amplifying the TMZ cytotoxicity. 
Overall the present study shows that inhibition of 
the integrin αVβ3 sensitizes glioma cells to TMZ, altering 
multiple molecular pathways like DNA repair, signaling 
and apoptosis. Thus αVβ3 targeting combined with 
TMZ is a valuable approach to improve TMZ therapy of 
malignant gliomas. 
MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board.
Cell culture
The human glioblastoma cell line U87MG was 
purchased from Cell Line Service (Eppelheim, Germany), 
and the glioblastoma cell line LN229 was obtained 
from LGC Standards (Wesel am Rhein, Germany). 
The glioblastoma cell lines LN308, LN319, LN428, 
LN18, D247MG and U138MG were kindly provided 
by Prof. Weller (Laboratory of Molecular Neuro-
Oncology, University Hospital and University of Zurich, 
Switzerland) and were characterized [20]. pSUPER-
Rad51sh transfected LN229 cells (LN229-Rad51kd) were 
previously described [23]. The cell lines were grown in 
Dulbecco’s modified Eagle’s medium with 10% fetal 
bovine serum (Invitrogen) at 37°C, 7% CO2.
Subcutaneous xenografts in nude mice
To induce subcutaneous xenografts, U87MG cells 
(2.5 × 106) were injected into both flanks of 8-week old 
immunodeficient mice (Balb/c nu/nu). When tumors 
reached a suitable size (22 mm3), animals were separated 
into four gender-mixed groups (2 mice per group): 1) 
Control group (1/4 DMSO to 3/4 PBS i.p.), 2) TMZ group 
(200 mg/kg body weight in DMSO/PBS i.p.), 3) RGD 
group (cyclo-RGD peptide, ∼500 µg i.p., administered 
only once), 4) RGD + TMZ group (∼500 µg RGD i.p. 
two hours prior to TMZ injection, 200 mg/kg body weight 
i.p.). Three weeks later the mice were sacrificed and tumor 
tissue disintegrated, as described [52]. We deliberately 
kept the number of animals at minimum since our goal 
was to verify the molecular mechanism, i.e. to prove 
expression of key repair and apoptotic players in regressed 
tumors and not to show regression on its own; the fact that 
under those circumstances (TMZ alone or TMZ+RGD) 
tumors regress has been repeatedly shown.
Drugs and chemicals 
TMZ was dissolved in DMSO (35 mM stock) 
and stored in aliquots at -80°C. The cyclo-RGD peptide 
(BML- AM100-0001, Enzo Life Sciences) was diluted in 
PBS. The proteasomal inhibitor MG132 and the NFκB 
inhibitor (Merck Millipore) were dissolved in DMSO 
(10  mM and 30.4 mM stock, respectively), stored in 
aliquots at –20°C and applied at 10 µM.
Determination of integrin expression by flow 
cytometry
Membrane fluorescence staining for αVβ3, 
αVβ5, α3β1 and α4β1 was performed using primary 
monoclonal antibodies against αVβ3, αVβ5, α3β1 and 
α4 (see Supplementary Table S1). The binding of the 
unlabeled antibodies was visualized by the secondary 
goat Alexa Fluor® 488-coupled anti-mouse antibody (see 
Supplementary Table S1). Acquisition was conducted 
using FACSCalibur (BD Biosciences).
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Transfection of small interfering RNA (siRNA)
For silencing of integrin subunits β3, β5, αV, α3 and 
α4, the predesigned integrin-specific siRNA sequences 
(Silencer Select Predesigned siRNA; Ambion; siRNA 
ID# s7581 (si(β3)), s7591 (si(β5)), s7568 (si(αV)), 
s7543 (si(α3)), s7544 (si(α4)) and control human non-
silencing siRNA (si(ns)) (Silencer Select Predesigned 
siRNA Negative Control #1 siRNA; Ambion) were 
used. The transfections of siRNAs were performed using 
Lipofectamine RNAiMAX Reagent (Invitrogen).
Determination of cell death
MTT and colony formation assay were conducted as 
described [52]. For drug-induced apoptosis and cell cycle 
distribution cells were fixed in 70% ethanol and treated 
with DNase-free RNase and stained with propidium iodide, 
as described [53]. Alternatively, to distinguish apoptosis 
from necrosis, annexin V-FITC/propidium iodide assay 
was conducted [53]. Frequency of apoptosis (subG1 and 
annexin V fractions) was determined by flow cytometry 
(FACSCanto II, BD Biosciences) using the Cell Quest 
Pro software. The caspase-3/7 activity was performed 
according to the manufacturer’s protocol (Caspase-Glo 
3/7 Assay, Promega). In brief, integrin-specific siRNA-
transfected cells were re-seeded into half white-bottom 
MTP (100 µL maximum volume), or alternatively directly 
seeded into MTP (500-1000 cells per well), and exposed 
to anticancer agents. After appropriate time for induction 
of apoptosis (120 h), the substrate was added directly to 
the medium with cells. One hour later, induction signal 
was determined fluorometrically. Acquired values were 
quantified as relative activity (x-fold induction) in TMZ-
exposed compared to non-exposed cells that were set to 1.
Determination of cell migration
Cell migration was evaluated using Transwell inserts 
(Corning). Serum starved (24 h) cells were placed in the 
upper chamber (8 × 104 cells in 0.5 mL DMEM containing 
0.1% BSA) and 1 mL of DMEM containing 10% FBS 
was placed in the lower chamber of 24-well plate. After 
22 h in culture, cells on the upper side of the filters were 
removed with cotton-tipped swabs, the filters were fixed 
in PFA for 15 min and stained with 1% crystal violet in 
PBS for 90 min. Cells on the underside of the filters were 
photographed under light microscope and counted.
HR activity assay 
Efficiency of HR was determined by a qPCR-based 
HR Assay kit (Norgen Biotek Corporation, ON, Canada), as 
described [54]. LN229 cells were transfected with siRNA 
and 18 h later exposed to 100 µM TMZ. 72 h later the cells 
were transfected with the HR plasmids and 24 h thereafter 
subjected to isolation of total cellular DNA. Samples were 
standardized with universal primers, detecting the plasmid 
backbone for control of transfection efficiency. 
NFκB activity assay
Cells were transfected with the firefly luciferase 
NFκB-specific reporter gene construct (3 × NFκB-
luciferase) [55] and co-transfected with a renilla luciferase 
reporter as an internal normalization control using 
Hyperfect Transfection Reagent (Qiagen). 
Preparation of cell extracts and western blot 
analysis
Whole-cell extracts were prepared by direct lysis 
with to 95°C heated 1x loading buffer (Roti-Load®, 
Roth), as described [53]. Proteins were separated by SDS-
PAGE and transferred onto a nitrocellulose membrane 
(Amersham) by wet blotting, blocked in 5% non-fat dry 
milk in TBS-Tween and incubated with specific antibodies. 
Protein signals were detected using ECL reagent (Pierce). 
Antibodies used for western blot analysis are specified in 
the Supplementary Table S1. 
Immunofluorescence 
Cells were seeded onto pre-cleaned cover slips 
in duplicates, transfected with siRNA and/or exposed 
to TMZ. Cells were washed in PBS and fixed with 4% 
paraformaldehyde for 15 min at RT. After washing with 
PBS, cells were incubated with ice-cold methanol for 
10 min at –20°C. After three washing steps with PBS, to 
avoid unspecific binding, the blocking reagent (PBS + 
0.25% Triton 100-X + 10% normal goat serum) was 
added for 1 h. The Rad51/yH2AX staining and evaluation 
was conducted as described [56]. After washing, nuclei 
were either stained with TO-PRO-3 (1:1000, 15 min; 
only for acquisition on LSM), or treated with 10 µL 
anti-fade medium (Vectashield) with DAPI (only for 
acquisition with Metafer system). For each treatment 
sample, 50 cells were analyzed. Microscopy images were 
screened and captured using Zeiss Axio Imager M1 (Carl 
Zeiss) supplied with the Metafer4 Software (MetaSystems, 
Altlussheim, Germany).
Statistics
The data were evaluated using two way analysis 
of variance (two-way ANOVA) followed by Bonferroni-
correction and were expressed as a mean ± SD. *p ≤ 0.05 
was considered statistically significant, **p ≤ 0.01 
very significant, ***p ≤ 0.005 highly significant and 
****p ≤ 0.001 most significant. Statistical analyses 
were performed using GraphPad Prism version 6.01 for 
Windows, GraphPad Software, La Jolla California USA 
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(www.graphpad.com).
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